相似文献
1
Vaccination with multimeric L2 fusion protein and L1 VLP or capsomeres to broaden protection against HPV infection.
Vaccine. 2010 Jun 17;28(28):4478-86. doi: 10.1016/j.vaccine.2010.04.039. Epub 2010 Apr 29.
2
Concatenated multitype L2 fusion proteins as candidate prophylactic pan-human papillomavirus vaccines.
J Natl Cancer Inst. 2009 Jun 3;101(11):782-92. doi: 10.1093/jnci/djp106. Epub 2009 May 26.
3
Broad Cross-Protection Is Induced in Preclinical Models by a Human Papillomavirus Vaccine Composed of L1/L2 Chimeric Virus-Like Particles.
J Virol. 2016 Jun 24;90(14):6314-25. doi: 10.1128/JVI.00449-16. Print 2016 Jul 15.
4
Durable immunity to oncogenic human papillomaviruses elicited by adjuvanted recombinant Adeno-associated virus-like particle immunogen displaying L2 17-36 epitopes.
Vaccine. 2015 Oct 13;33(42):5553-5563. doi: 10.1016/j.vaccine.2015.09.005. Epub 2015 Sep 15.
5
Immunization with a consensus epitope from human papillomavirus L2 induces antibodies that are broadly neutralizing.
Vaccine. 2014 Jul 23;32(34):4267-74. doi: 10.1016/j.vaccine.2014.06.054. Epub 2014 Jun 21.
6
Optimization of multimeric human papillomavirus L2 vaccines.
PLoS One. 2013;8(1):e55538. doi: 10.1371/journal.pone.0055538. Epub 2013 Jan 31.
7
Capsid display of a conserved human papillomavirus L2 peptide in the adenovirus 5 hexon protein: a candidate prophylactic hpv vaccine approach.
Virol J. 2015 Sep 11;12:140. doi: 10.1186/s12985-015-0364-7.
8
Preclinical refinements of a broadly protective VLP-based HPV vaccine targeting the minor capsid protein, L2.
Vaccine. 2015 Jun 26;33(29):3346-53. doi: 10.1016/j.vaccine.2015.05.016. Epub 2015 May 21.
9
Minor Capsid Protein L2 Polytope Induces Broad Protection against Oncogenic and Mucosal Human Papillomaviruses.
J Virol. 2018 Jan 30;92(4). doi: 10.1128/JVI.01930-17. Print 2018 Feb 15.
10
Developments in L2-based human papillomavirus (HPV) vaccines.
Virus Res. 2017 Mar 2;231:166-175. doi: 10.1016/j.virusres.2016.11.020. Epub 2016 Nov 23.
引用本文的文献
1
Prophylactic vaccines against HPV-caused cervical cancer: novel vaccines are still demanded.
Infect Agent Cancer. 2025 Mar 10;20(1):16. doi: 10.1186/s13027-025-00643-5.
2
New Perspectives in Therapeutic Vaccines for HPV: A Critical Review.
Medicina (Kaunas). 2022 Jun 28;58(7):860. doi: 10.3390/medicina58070860.
3
Mixed Bacteriophage MS2-L2 VLPs Elicit Long-Lasting Protective Antibodies against HPV Pseudovirus 51.
Viruses. 2021 Jun 10;13(6):1113. doi: 10.3390/v13061113.
4
RG1-VLP and Other L2-Based, Broad-Spectrum HPV Vaccine Candidates.
J Clin Med. 2021 Mar 3;10(5):1044. doi: 10.3390/jcm10051044.
5
Progress in L2-Based Prophylactic Vaccine Development for Protection against Diverse Human Papillomavirus Genotypes and Associated Diseases.
Vaccines (Basel). 2020 Oct 1;8(4):568. doi: 10.3390/vaccines8040568.
6
Interaction Between Virus-Like Particles (VLPs) and Pattern Recognition Receptors (PRRs) From Dendritic Cells (DCs): Toward Better Engineering of VLPs.
Front Immunol. 2020 Jun 9;11:1100. doi: 10.3389/fimmu.2020.01100. eCollection 2020.
7
Virus-like Particle-Based L2 Vaccines against HPVs: Where Are We Today?
Viruses. 2019 Dec 23;12(1):18. doi: 10.3390/v12010018.
8
Rational design of a triple-type human papillomavirus vaccine by compromising viral-type specificity.
Nat Commun. 2018 Dec 18;9(1):5360. doi: 10.1038/s41467-018-07199-6.
9
A novel candidate HPV vaccine: MS2 phage VLP displaying a tandem HPV L2 peptide offers similar protection in mice to Gardasil-9.
Antiviral Res. 2017 Nov;147:116-123. doi: 10.1016/j.antiviral.2017.09.012. Epub 2017 Sep 20.
10
Incorporation of RG1 epitope concatemers into a self-adjuvanting Flagellin-L2 vaccine broaden durable protection against cutaneous challenge with diverse human papillomavirus genotypes.
Vaccine. 2017 Sep 5;35(37):4942-4951. doi: 10.1016/j.vaccine.2017.07.086. Epub 2017 Aug 1.
本文引用的文献
1
Comparison of the immunogenicity and safety of Cervarix and Gardasil human papillomavirus (HPV) cervical cancer vaccines in healthy women aged 18-45 years.
Hum Vaccin. 2009 Oct;5(10):705-19. doi: 10.4161/hv.5.10.9518. Epub 2009 Oct 14.
2
Efficacy of human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine against cervical infection and precancer caused by oncogenic HPV types (PATRICIA): final analysis of a double-blind, randomised study in young women.
Lancet. 2009 Jul 25;374(9686):301-14. doi: 10.1016/S0140-6736(09)61248-4. Epub 2009 Jul 6.
3
Modulation of adaptive immunity with Toll-like receptors.
Semin Immunol. 2009 Aug;21(4):185-93. doi: 10.1016/j.smim.2009.05.005. Epub 2009 Jun 6.
4
Concatenated multitype L2 fusion proteins as candidate prophylactic pan-human papillomavirus vaccines.
J Natl Cancer Inst. 2009 Jun 3;101(11):782-92. doi: 10.1093/jnci/djp106. Epub 2009 May 26.
5
Analysis of modified human papillomavirus type 16 L1 capsomeres: the ability to assemble into larger particles correlates with higher immunogenicity.
J Virol. 2009 Aug;83(15):7690-705. doi: 10.1128/JVI.02588-08. Epub 2009 May 20.
6
Developing vaccines against minor capsid antigen L2 to prevent papillomavirus infection.
Immunol Cell Biol. 2009 May-Jun;87(4):287-99. doi: 10.1038/icb.2009.13.
7
The impact of quadrivalent human papillomavirus (HPV; types 6, 11, 16, and 18) L1 virus-like particle vaccine on infection and disease due to oncogenic nonvaccine HPV types in generally HPV-naive women aged 16-26 years.
J Infect Dis. 2009 Apr 1;199(7):926-35. doi: 10.1086/597307.
8
Refining HPV 16 L1 purification from E. coli: reducing endotoxin contaminations and their impact on immunogenicity.
Vaccine. 2009 Mar 4;27(10):1511-22. doi: 10.1016/j.vaccine.2009.01.014. Epub 2009 Jan 25.
9
Papillomaviruses in the causation of human cancers - a brief historical account.
Virology. 2009 Feb 20;384(2):260-5. doi: 10.1016/j.virol.2008.11.046. Epub 2009 Jan 8.
10
A direct comparison of human papillomavirus type 16 L1 particles reveals a lower immunogenicity of capsomeres than viruslike particles with respect to the induced antibody response.
J Virol. 2008 Jun;82(11):5472-85. doi: 10.1128/JVI.02482-07. Epub 2008 Apr 2.
Zotero 插件